These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 6321836

  • 1. Hyperalgesic effect of the selective kappa opioid agonist, U-50488H in mice.
    Ramabadran K.
    Jpn J Pharmacol; 1983 Dec; 33(6):1289-92. PubMed ID: 6321836
    [No Abstract] [Full Text] [Related]

  • 2. U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists.
    Von Voigtlander PF, Lewis RA.
    Prog Neuropsychopharmacol Biol Psychiatry; 1982 Dec; 6(4-6):467-70. PubMed ID: 6298890
    [Abstract] [Full Text] [Related]

  • 3. Multi-dimensional analyses of behavior in mice treated with U-50,488H, a purported kappa (non-mu) opioid agonist.
    Ukai M, Kameyama T.
    Brain Res; 1985 Jul 01; 337(2):352-6. PubMed ID: 2992682
    [Abstract] [Full Text] [Related]

  • 4. A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats.
    Yamamoto T, Ohno M, Ueki S.
    Eur J Pharmacol; 1988 Oct 26; 156(1):173-6. PubMed ID: 2850208
    [Abstract] [Full Text] [Related]

  • 5. Stereospecific inhibition of gastrointestinal transit by kappa opioid agonists in mice.
    Ramabadran K, Bansinath M, Turndorf H, Puig MM.
    Eur J Pharmacol; 1988 Oct 18; 155(3):329-31. PubMed ID: 2853069
    [Abstract] [Full Text] [Related]

  • 6. Strain differences in the hyperalgesic effect of a novel kappa receptor agonist, U-50488H in mice.
    Ramabadran K.
    Eur J Pharmacol; 1984 Mar 02; 98(3-4):425-7. PubMed ID: 6327334
    [Abstract] [Full Text] [Related]

  • 7. The opioid kappa-selective compound U-50,488H does not inhibit intestinal propulsion in rats.
    Tavani A, Gambino MC, Petrillo P.
    J Pharm Pharmacol; 1984 May 02; 36(5):343-4. PubMed ID: 6145777
    [Abstract] [Full Text] [Related]

  • 8. Kappa-opioid peptide receptor stimulation increases cytosolic pH and myofilament responsiveness to Ca2+ in cardiac myocytes.
    Ventura C, Capogrossi MC, Spurgeon HA, Lakatta EG.
    Am J Physiol; 1991 Nov 02; 261(5 Pt 2):H1671-4. PubMed ID: 1659231
    [Abstract] [Full Text] [Related]

  • 9. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
    Craft RM, Dykstra LA.
    J Pharmacol Exp Ther; 1992 Jan 02; 260(1):327-33. PubMed ID: 1309876
    [Abstract] [Full Text] [Related]

  • 10. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
    Picker MJ, Doty P, Negus SS, Mattox SR, Dykstra LA.
    J Pharmacol Exp Ther; 1990 Jul 02; 254(1):13-22. PubMed ID: 2164087
    [Abstract] [Full Text] [Related]

  • 11. Agonist and antagonist activity of kappa opioids in the squirrel monkey: II. Effect of chronic morphine treatment.
    Craft RM, Dykstra LA.
    J Pharmacol Exp Ther; 1992 Jan 02; 260(1):334-42. PubMed ID: 1309877
    [Abstract] [Full Text] [Related]

  • 12. Probes for narcotic receptor mediated phenomena. 17. Synthesis and evaluation of a series of trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacet amide (U50,488) related isothiocyanate derivatives as opioid receptor affinity ligands.
    de Costa BR, Rothman RB, Bykov V, Band L, Pert A, Jacobson AE, Rice KC.
    J Med Chem; 1990 Apr 02; 33(4):1171-6. PubMed ID: 2157008
    [Abstract] [Full Text] [Related]

  • 13. Biochemical and functional interactions of a selective kappa opioid agonist with calcium.
    VonVoigtlander PF, Ochoa MC, Lewis RA.
    Adv Exp Med Biol; 1987 Apr 02; 221():345-55. PubMed ID: 2829584
    [Abstract] [Full Text] [Related]

  • 14. Role of spinal kappa opioid receptors in the blockade of the development of antinociceptive tolerance to morphine.
    Takahashi M, Senda T, Kaneto H.
    Eur J Pharmacol; 1991 Aug 06; 200(2-3):293-7. PubMed ID: 1664330
    [Abstract] [Full Text] [Related]

  • 15. Selective kappa opioid agonist for spinal analgesia without the risk of respiratory depression.
    Castillo R, Kissin I, Bradley EL.
    Anesth Analg; 1986 Apr 06; 65(4):350-4. PubMed ID: 3006552
    [Abstract] [Full Text] [Related]

  • 16. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine.
    Krulich L, Koenig JI, Conway S, McCann SM, Mayfield MA.
    Neuroendocrinology; 1986 Apr 06; 42(1):75-81. PubMed ID: 3001565
    [Abstract] [Full Text] [Related]

  • 17. Selectivity for opioid receptor subtypes of enkephalin analogues in isolated smooth muscle and in the analgesic effect in mice.
    Watanabe J, Takahashi M, Maeda M, Kawasaki K, Kaneto H.
    J Pharmacobiodyn; 1989 Sep 06; 12(9):544-8. PubMed ID: 2559186
    [Abstract] [Full Text] [Related]

  • 18. Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid.
    Vonvoigtlander PF, Lewis RA.
    J Pharmacol Exp Ther; 1988 Jul 06; 246(1):259-62. PubMed ID: 2839665
    [Abstract] [Full Text] [Related]

  • 19. Similar actions of kappa and mu agonists on spinal nociceptive reflexes in rats and their reversibility by naloxone.
    Parsons CG, West DC, Headley PM.
    NIDA Res Monogr; 1986 Jul 06; 75():461-4. PubMed ID: 2828992
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.